DALLAS, Oct. 20, 2009 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring biopharmaceutical company Cardium Therapeutics Inc. (AMEX:CXM). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
The investment report on Cardium Therapeutics Inc. (AMEX:CXM) should be of particular interest to other biopharmaceutical companies: Biogen Idec Inc. (Nasdaq:BIIB), Celgene Company (Nasdaq:CELG) and Cephalon Inc. (Nasdaq:CEPH).
It is available at: http://www.beaconequity.com/i/CXM
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
Cardium Therapeutics Inc. (CXM) is a biopharmaceutical company engaged in the development and commercialization of novel biological therapeutics and devices for the treatment of cardiovascular and ischemic diseases. The Company has acquired three business units, Cardium Biologics, InnerCool Therapies, and Tissue Repair Company, to establish a portfolio of late-stage cardiovascular and regenerative medicine candidates.
In the report, the analyst notes:
"The Company's lead candidate Generx is developed for the treatment of myocardial ischemia and angina symptoms associated with coronary heart disease. Generx is a new class of biologics to promote blood flow following cardiac infusion catheter surgical procedures.
"Generx is in phase III AWARE clinical studies, a randomized, placebo-controlled, and double-blind study involving approximately 300 women afflicted with recurrent stable angina pectoris. The women subjects are on a regimen of drug therapies, as are candidates for revascularization.
"On October 15, the Company announced a common stock offering to select investors valued at $6 million of gross proceeds. Securities and Exchange Commission (SEC) documents show that the Company issued 4.61 million shares at a price of $1.30, with warrants to purchase additional shares of no more than 3 million shares at an exercised price of $1.40."
To read the entire report visit: http://www.beaconequity.com/i/CXM
See what investors are saying about these stocks at: http://www.stockhideout.com/
BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. BeaconEquity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.